With a platform that can predict which drug candidates will work in humans—and eliminate the costly and inefficient practice of testing on animals—Quris hopes to revolutionize drug development.
Like businesses in any other industry, pharmaceutical companies compete with each other. Despite their individual races to the finish line, the mission is the same: develop and produce lifesaving and life-changing treatments that move medicine, and humanity, forward. The recognition of this mutual goal, and the potential of breaking down siloes to share information, has…
This week Israel-based AION Labs, an AI-enabled drug discovery partnership between global pharma and tech companies like AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services, announced the formation of a new startup company dubbed OMEC.AI.
OMEC.AI aims to build a computational platform using AI that can help researchers assess the clinical trial readiness…
OMEC.AI is the first company to be formed by Israel -based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS), powered by BioMed X
OMEC.AI will use advanced machine learning to improve probability of success for drug candidates in clinical trials
REHOVOT, Israel , Sept. 28, 2022 …
Pharmaceutical giants Pfizer, AstraZeneca, Merck and Teva Pharmaceuticals, together with tech giant Amazon Web Services and the Israel Biotech Fund, officially opened a new innovation lab in Israel this week that will foster the creation of new startups developing cutting-edge AI-based computational technologies to help find personalized drugs and treatments for patients.
The facility, dubbed…
Insilico closes $255 million to progress into human clinical trials and develop novel targets and also announces Teva Pharm collaboration. Insilico Medicine, a company driving end-to-end AI for target discovery, small molecule chemistry and clinical development, has announced that it has closed $255 million from biotechnology experts to progress Insilico Medicine’s current therapeutic programmes into…
image: Insilico collaborates with Teva.
view more
Credit: Insilico Medicine
…
image: The expansion of Dr. Bayewitch’s role is part of Insilico’s evolving BD strategy, focusing on asset partnering and out-licensing.
view more
…